Dishman Carbogen Peer Comparison

NSE: DCAL | BSE: 540701

₹157.40

₹2.59 (1.67%)

As on 05-Nov-2026 13:49IST

Market cap

₹2,501 Cr

Revenue (TTM)

₹2,901 Cr

P/E Ratio

154.8

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Market cap (₹ Cr)	2,501	275	176	32	18
Revenue (₹ Cr)	2,901	145	85	55	0
Net Profit (₹ Cr)	16.16	-4.90	12.82	-2.86	--
Net Margin (%)	0.55	-3.31	6.38	-5.15	-0.79
RoE (%)	0.29	-4.53	20.84	-16.06	-0.03
Price to Earnings	154.79	--	13.75	--	--
Price-To-Book	0.38	2.87	5.50	0.35	4.55

Income Statement (₹ Cr)

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Operating Revenue	2,931.90	128.44	54.19	53.33	0.84
Total Income	2,987.84	131.94	60.87	53.78	0.85
Total Expenditure	2,366.27	131.93	56.10	32.43	0.40
EBITDA	565.63	-3.49	-1.91	20.91	0.44
Depreciation	338.69	8.46	0.01	10.63	0.00
EBIT	226.94	-11.95	-1.92	10.28	0.44
Interest	174.18	3.33	0.35	5.91	0.00
Other Income	55.94	3.50	6.69	0.44	0.00
Exceptional Items	-3.80	--	--	--	--
Profit before Tax	104.90	-11.78	4.42	4.81	0.44
Provision for Tax	7.45	-1.34	0.16	6.52	0.09
Profit after Tax	97.45	-10.44	4.26	-1.71	0.36

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Shareholder's Funds	6,676.90	92.39	31.00	93.16	3.90
Minority Interest	--	-1.56	0.00	--	--
Non-Current Liabilities	2,846.00	29.81	0.00	55.04	0.00
Current Liabilities	2,317.05	53.90	5.24	30.23	0.46
Total Liabilities	11,911.40	174.54	36.24	178.43	4.36

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Non-Current Assets	8,997.85	111.26	12.48	149.74	1.73
Current Assets	2,842.10	63.28	23.77	28.42	2.62
Total Assets	11,911.40	174.54	36.24	178.43	4.36
Total Debt*	2,775.40	48.36	0.00	67.38	0.00
Net Current Assets	525.05	9.38	18.53	-1.82	2.16
Contingent Liabilities	428.74	37.44	--	--	--

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Cash From Operating Activities	491.45	5.24	-4.13	34.93	0.03
Cash Flow from Investing Activities	-245.34	-9.41	1.74	-59.35	0.01
Cash from Financing Activities	200.58	4.19	-0.72	24.57	--
Net Cash Inflow / Outflow	446.69	0.02	-3.11	0.15	0.04

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
ROCE (%)	3.21	-5.96	18.49	7.34	11.87
ROE (%)	1.56	-10.64	16.52	-2.11	9.57
ROA (%)	0.89	-5.95	11.71	-1.06	8.20
EBIT Margin (%)	21.20	0.01	8.81	40.03	52.63
Net Margin (%)	3.26	-7.91	6.99	-3.18	41.97
Cash Profit Margin (%)	14.88	-1.54	7.87	16.72	42.50

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Revenue Growth (%)	8.13	-7.26	-100.00	14.27	411.25
EBIT Growth (%)	26.69	-99.94	73.95	-15.82	2,529.91
Net Profit Growth (%)	2,907.72	-231.54	476.63	-123.46	2,245.51
EPS Growth (%)	2,908.18	-225.21	-71.28	-118.15	2,245.67
Book Value Growth (%)	14.50	-11.84	51.02	29.61	10.05

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Price / Earnings	20.92	0.00	53.86	0.00	50.26
Price / Book Value	0.31	1.74	18.91	0.51	4.59
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	6.15	0.00	122.77	5.28	40.19
Market Cap (₹ Cr)	2,038.26	159.68	586.26	46.71	17.90

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debt to Equity	0.42	0.53	0.00	0.74	0.00
Short term debt to equity ratio	0.13	0.21	--	0.13	--
Current Ratio	1.23	1.17	4.54	0.94	5.73
Quick Ratio	0.79	0.92	4.54	0.67	5.11
Interest Coverage	1.60	-2.54	13.66	1.81	2,845.31

	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech	Genomic Biotech
Debtors to sales (%)	22.95	27.28	0.40	22.03	262.40
Asset Turnover	0.27	0.73	1.49	0.33	0.19
Receivable days	83.29	110.99	1.47	78.69	1,026.01
Inventory Days	119.47	37.08	0.00	54.55	122.93
Payable days	197.26	115.42	9.35	66.07	554.30
Cash Conversion Cycle	5.50	32.64	-7.88	67.17	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.